Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.90
+0.04 (0.24%)
Jul 28, 2026, 12:28 PM EDT - Market open
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $17.70M in the quarter ending March 31, 2026, with 15.02% growth. This brings the company's revenue in the last twelve months to $109.78M, up 68.20% year-over-year. In the year 2025, Theravance Biopharma had annual revenue of $107.46M with 66.92% growth.
Revenue (ttm)
$109.78M
Revenue Growth
+68.20%
P/S Ratio
7.96
Revenue / Employee
$1,219,722
Employees
90
Market Cap
875.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.46M | 43.08M | 66.92% |
| Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
| Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
| Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
| Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
| Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
| Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
| Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
| Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
| Dec 31, 2016 | 48.65M | 6.52M | 15.48% |
| Dec 31, 2015 | 42.13M | 30.44M | 260.42% |
| Dec 31, 2014 | 11.69M | 11.46M | 5,071.68% |
| Dec 31, 2013 | 226.00K | -129.92M | -99.83% |
| Dec 31, 2012 | 130.15M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Arbutus Biopharma | 191.45M |
| Kura Oncology | 71.64M |
| Janux Therapeutics | 13.73M |
| DBV Technologies | 5.04M |
| Odyssey Therapeutics | 1.06M |
TBPH News
- 21 days ago - Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 4 weeks ago - Zymeworks price target raised to $37 from $35 at Citi - TheFly
- 4 weeks ago - Theravance Biopharma downgraded to Neutral from Buy at BTIG - TheFly
- 4 weeks ago - Theravance Biopharma downgraded to Hold from Buy at JonesResearch - TheFly
- 4 weeks ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 4 weeks ago - Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline - Barrons
- 4 weeks ago - M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B - TipRanks
- 4 weeks ago - Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash - TheFly